Skip to main content


1. Mahid SS, Mulhall AM, Gholson RD, et al.: Inflammatory bowel disease and African Americans: a
systematic review. Inflamm Bowel Dis 2008;14:960-967.
2. Porter CK, Tribble DR, Aliaga PA, et al.: Infectious gastroenteritis and risk of developing inflammatory
bowel disease. Gastroenterology 2008;135:781-786.
3. Risques RA, Lai LA, Brentnall TA, et al.: Ulcerative colitis is a disease of accelerated colon aging:
evidence from telomere attrition and DNA damage. Gastroenterology 2008;135:410-418.
4. Bitton A, Dobkin PL, Edwardes MD, et al.: Predicting relapse in Crohn’s disease: a biopsychosocial
model. Gut 2008;57:1386-1392.
5. Allison J, Herrington LJ, Liu L, et al.: Natural history of severe ulcerative colitis in a community-based
health plan. Clin Gastroenterol Hepatol 2008;6:999-1003.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 192
A vastagbél 193
6. Vernier-Massouille G, Balde M, Salleron J, et al.: Natural history of pediatric Crohn’s disease: a
population-based cohort study. Gastroenterology 2008;135:1106-1113.
7. van Limbergen J, Russel RK, Drummond HE, et al.: Definition of phenotypic charasteristics of
childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114-1122.
8. Bernstein CN, Wajda A, Blanchard JF.: The incidence of arterial thromboembolic diseases in inflammatory
bowel disease: a population-based study. Clin Gastroenterol Hepatol 2008;6:41-45.
9. Issa M, Ananthakrishnan AN, Binion DG.: Clostridium difficile and inflammatory bowel disease.
Inflamm Bowel Dis 2008;14:1432-1442.
10. Higgins PDR, Rubin DT, Kaulback K, et al.: Systematic review: impact of non-adherence to 5-aminosalicilyc
acid products ont he frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther
11. Gisbert JP, Nino P, Cara C, Rodrigo L.: Comparative effectiveness of azathioprine in Crohn’s disease
and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther
12. Akonbeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn’s
disease. Alimentary Pharmacol Ther 2008;27:11-18.
13. D”Haens GR, Vermeire S, van Assche G, et al.: Therapy of metronidazole with azathioprine to prevent
postoperative recurrence of Crohn’s disease: a controlled randomized study Gastroenterology
14. Ansari A, Arenas M, Greenfield SM, et al.: Prospective evaluation of the pharmacogenetics of azathioprine
in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:973-983.
15. Chrostensen LA, Dahlerup JF, Nielsen MJ, et al.: Azathioprine treatment during lactation. Aliment
Pharmacol Ther 2008;28:1209-1213.
16. Lees CW, Maan AK, Hansoti B, et al.: Tolerability and safety of mercaptopurine in azathioprine-intolerant
patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008;27:220-227.
17. Din S, Dahele A, Fennel J, et al.: Use of methotrexate in refractory Crohn’s disease: the Edinburgh
experience. Inflamm Bowel Dis 2008;14:756-762.
18. Maser EA, Deconda D, Lichtiger S, et al.: Cyclosporine and infliximab as rescue therapy for each other
in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008;6:1112-1116.
19. Lewis JD, Lichtenstein GR, Deren JJ, et al.: Rosiglitazone for active ulcerative colitis: a randomized
placebo-controlled trial. Gastroenterology 2008;134:688-695.
20. Sands BE, Sandborn WJ, Feagan B, et al.:Aized, double-blind, sham-controlled study of granulocyta/monocyte
apheresis for active ulcerative colitis. Gastroenterology 2008;135:400-409.
21. Siegel CA, Levy LC, MacKenzie TA, Sands BE.: Patient perceptions of the risks and benefits of infliximab
for the treatment of inflammatory bowel disease. IBD 2008;14:1-6.
22. Toruner M, Loftus EV Jr, Harmsen WS, et al.: Risk factors for opportunistic infections in patients with
inflammatory bowel disease. Gastroenterology 2008;134:929-936.
23. Gerasimidis K, McGrogan P, Hassan K, Edwards CA.: Dietary modifications, nutritional supplements
and alternative medicine in paediatric patients with inflammatory bowel disease. Aliment Pharmacol
Ther 2008;27:155-165.
24. Cullen G, O’Toole A, Keegan D, et al.: Long-term clinical results of ileocoecal resection for Crohn’s
disease. IBD 2007;13:1369-1373.
25. Domenech E, Manosa M, Bernal I, et al.: Impact of azathioprine on the prevention of postoperative
Gastro 2009.qxd 5/9/2009 1:41 PM Page 193
194 Gastro Update 2009
Crohn’s disease recurrence: results of a prospective, observational, long-term follow-up study. Inflamm
Bowel Dis 2008;14:508-513.
26. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al.: Direct health care costs of Crohn’s disease and
ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-1913.
27. Friedman S, Rubin PH, Bodian C, Present DH.: Screening and surveillance colonoscopy in chronic
Crohn’s colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol
28. Botteri E, Iodice S, Bagnardi V, et al.: Smoking and colorectal cancer. A meta-analysis. JAMA
29. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C.: Systematic review: primary and secondary prevention
of gastrointestinal cancers with antioxidant supplements. Aliment Pharmacol The 2008;28:689-703.
30. Soest EM, van Rossum, Dieleman JP, et al.: Proton pump inhibitors and the risk of colorectal cancer.
Am J Gastroenterol 2008;103:966-973.
31. Kaltenbach T, Friedland S, Soetikno R.: A randomised tandem colonoscopy trial of narrow band imaging
versus white light examination to compare neoplasia miss rate. Gut 2008;57:1406-1412.
32. Kahi CJ, Rex DK,: Imperiale TF. Screening, surveillance, and primary prevention for colorectal cancer:
a review of the recent literature. Gastroenterology 2008;135:380-399.
33. Imperiale TF, Glowinski EA, Lin-Cooper C, et al.: Five-year risk of colorectal neoplasia after negative
screening colonoscopy. N Engl J Med 2008;359:1218-1224.
34. Rundle AG, Lebwohl B, Vogel R, et al.: Colonoscopic screening in average-risk individuals ages 40 to
49 vs 50 to 59 years. Gastroenterology 2008;134:1311-1315.
35. Pendergrass CJ, Edelstein DL, Hylind LM, et al.: Occurence of colorectal adenoma sin younger adults:
an epidemiologic necropsy study. Clin Gastroenterol Hepatol 2008;6:1011-1015.
36. Sawhney MS, Cury MS, Neeman N, et al.: Effect of institution-wide policy of colonoscopy withdrawal
time ?7 minutes on polyp detection. Gastroenterology 2008;135:1892-1898.
37. Burn J, Bishop T, Mecklin J_P, et al.: Effect of aspirin or resistant starch on colorectal neoplasia in the
Lynch syndrome. N Eng J Med 2008;359:2567-3578.
38. Niewenhuis MH, Nederveen Cappel WDVT, Botma A, et al.: Desmoid tumor sin a Dutch cohort of
patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008;6:215-219.
39. Ford AC, Talley NJ, Spiegel BMR, et al.: Effect of fibre, antispasmodics, and peppermint oil int he treatment
of irritable bowel syndrome: systemic review and meta-analysis. BMJ 2008;337:1388-1392.
40. Vahedi H, Merat S, Momtahen S, et al.: Clinical trial: the effect of amitriptyline in patients with
diarrhoea-predominant irritablée bowel syndrome. Aliment Pharmacol Ther 2008;27:678-684.
41. Hu MY, Maroo S, Kyne N, et al.: A prospective study of risk factors and historical trend sin metronidazole
failure for Clostridium difficile infection. Clin Gastroenterol Hepatol 2008;6:1354-1360.
42. Strate LL, Ayanian JZ, Kotler G, Syngal S.: Risk factors for mortality in lower intestinal bleeding. Clin
Gastroenterol Hepatol 2008;6:1004-1010.